Cite

HARVARD Citation

    Zundelevich, A. et al. (n.d.). 17P Using ex vivo organ culture technology to evaluate a T cell bispecific (TCB) CEACAM5 therapy. Immuno-oncology technology. p. . [Online]. 
  
Back to record